BIOGF: AI 评分 52/100 — AI 分析 (4月 2026)

Biocartis Group NV is a molecular diagnostics company focused on oncology, offering diagnostic solutions through its Idylla platform. The company collaborates with pharmaceutical firms to enhance treatment selection and monitoring.

Key Facts: AI Score: 52/100 Sector: Healthcare

公司概况

概要：

Biocartis Group NV specializes in molecular diagnostics with its Idylla platform, providing rapid and actionable molecular information for oncology and infectious diseases. The company partners with pharmaceutical giants like Amgen and Bristol-Myers Squibb to enhance treatment selection and monitoring, operating within the competitive medical diagnostics sector.

BIOGF是做什么的？

Biocartis Group NV, established in 2007 and headquartered in Mechelen, Belgium, is a molecular diagnostics company focused on transforming clinical practice through innovative diagnostic solutions. The company's core offering is the Idylla platform, a real-time polymerase chain reaction (PCR) system designed to provide rapid and accurate molecular information. This platform enables clinicians to make informed treatment decisions and monitor treatment progress, particularly in oncology. Biocartis offers a range of tests for the Idylla platform, including assays for BRAF, KRAS, MSI, EGFR, and NRAS-BRAF mutations, which are critical biomarkers in cancer. Additionally, the company provides tests for infectious diseases, such as the Idylla SARS-CoV-2/Flu/RSV panel and SARS-CoV-2 tests, as well as the SeptiCyte RAPID test for rapid host-response assessment. Biocartis collaborates with pharmaceutical companies like Amgen and Bristol-Myers Squibb to develop and commercialize diagnostic tests for targeted therapies. These partnerships leverage the Idylla platform's capabilities to accelerate access to biomarker information and improve patient outcomes. The company also provides research products, including various mutation assays for research purposes. Biocartis aims to enhance clinical practice by providing rapid, accurate, and actionable molecular information, benefiting patients, clinicians, payers, and the healthcare industry as a whole.

BIOGF的投资论点是什么？

Biocartis Group NV presents a compelling investment thesis based on its innovative Idylla platform and strategic collaborations. The company's focus on rapid molecular diagnostics in oncology and infectious diseases addresses a critical need in healthcare. Key value drivers include the expansion of the Idylla platform's test menu and the growth of its installed base. The collaborations with Amgen and Bristol-Myers Squibb for biomarker testing and immuno-oncology therapies represent significant growth catalysts. However, the company's negative profit margin of -113.7% and reliance on partnerships pose potential risks. The company's market capitalization is approximately $0.07 billion. The beta of 1.39 indicates higher volatility compared to the market. Successful execution of its commercial strategy and continued innovation in diagnostic solutions are crucial for realizing the company's long-term potential.

BIOGF在哪个行业运营？

Biocartis Group NV operates in the rapidly evolving medical diagnostics and research industry. The market is driven by increasing demand for personalized medicine, advancements in molecular diagnostics, and the need for rapid and accurate diagnostic solutions. The competitive landscape includes companies like EEOIF, GDNSF, HRPMF, KDEVF, and KIARF, as well as larger players in the diagnostics market. Biocartis differentiates itself through its Idylla platform, which offers rapid and easy-to-use molecular testing. The industry is expected to continue growing, driven by technological advancements and increasing healthcare expenditure. Biocartis's success depends on its ability to innovate, expand its test menu, and establish strategic partnerships.

Medical - Diagnostics & Research

Healthcare

BIOGF有哪些增长机遇？

Expansion of Idylla Platform Test Menu: Biocartis has the opportunity to expand its Idylla platform's test menu to include additional biomarkers and diagnostic assays. This would broaden the platform's applicability and attract a wider range of customers. The market for molecular diagnostics is expected to grow, driven by the increasing demand for personalized medicine. The timeline for expanding the test menu is ongoing, with new tests being developed and launched regularly. A competitive advantage lies in the platform's ease of use and rapid turnaround time.
Strategic Partnerships with Pharmaceutical Companies: Biocartis can leverage its Idylla platform to establish strategic partnerships with pharmaceutical companies for companion diagnostics and biomarker testing. These partnerships can provide access to new markets and revenue streams. The market for companion diagnostics is growing rapidly, driven by the increasing use of targeted therapies. The timeline for establishing new partnerships is ongoing, with potential deals being evaluated and negotiated regularly. A competitive advantage lies in the platform's ability to provide rapid and accurate biomarker information.
Geographic Expansion: Biocartis has the opportunity to expand its geographic presence by entering new markets and regions. This would increase the company's customer base and revenue potential. The global market for molecular diagnostics is growing, with significant opportunities in emerging markets. The timeline for geographic expansion is ongoing, with potential new markets being evaluated and targeted. A competitive advantage lies in the platform's ease of use and suitability for decentralized testing.
Development of New Diagnostic Solutions: Biocartis can invest in the development of new diagnostic solutions and technologies to address unmet needs in healthcare. This would enhance the company's product portfolio and attract new customers. The market for innovative diagnostic solutions is growing, driven by the increasing demand for personalized medicine. The timeline for developing new solutions is ongoing, with research and development efforts focused on emerging technologies. A competitive advantage lies in the company's expertise in molecular diagnostics and its established Idylla platform.
Focus on Infectious Disease Testing: Biocartis can capitalize on the growing demand for rapid and accurate infectious disease testing by expanding its Idylla platform's capabilities in this area. This would address a critical need in healthcare and provide a new revenue stream. The market for infectious disease testing is growing, driven by the emergence of new pathogens and the need for rapid diagnosis. The timeline for expanding infectious disease testing is ongoing, with new tests being developed and launched regularly. A competitive advantage lies in the platform's ability to provide rapid and accurate results.

Market capitalization of $0.07 billion indicates a small-cap company with potential for growth.
Negative P/E ratio of -0.27 reflects current unprofitability, requiring careful monitoring of future earnings.
Gross margin of 48.2% demonstrates the company's ability to generate revenue above the cost of goods sold.
Profit margin of -113.7% highlights significant operational challenges and the need for improved cost management.
Beta of 1.39 suggests higher volatility compared to the market, appealing to risk-tolerant investors.

BIOGF提供哪些产品和服务？

Develops and commercializes the Idylla platform for rapid molecular diagnostics.
Offers a range of diagnostic tests for oncology, including BRAF, KRAS, MSI, EGFR, and NRAS-BRAF mutation tests.
Provides tests for infectious diseases, such as SARS-CoV-2/Flu/RSV panels and SARS-CoV-2 tests.
Offers the SeptiCyte RAPID test for rapid host-response assessment.
Provides research products, including various mutation assays for research purposes.
Collaborates with pharmaceutical companies to develop and commercialize diagnostic tests for targeted therapies.
Focuses on enhancing clinical practice by providing rapid, accurate, and actionable molecular information.

BIOGF如何赚钱？

Sales of Idylla platform instruments and consumables.
Revenue from diagnostic tests for oncology and infectious diseases.
Partnerships with pharmaceutical companies for companion diagnostics and biomarker testing.
Sales of research products, including mutation assays.

Hospitals and clinical laboratories.
Pharmaceutical companies.
Research institutions.
Healthcare providers.

Proprietary Idylla platform technology.
Established partnerships with pharmaceutical companies.
Rapid and accurate diagnostic results.
Focus on oncology and infectious diseases.

什么因素可能推动BIOGF股价上涨？

Ongoing: Expansion of the Idylla platform's test menu to include additional biomarkers and diagnostic assays.
Ongoing: Strategic partnerships with pharmaceutical companies for companion diagnostics and biomarker testing.
Upcoming: Potential regulatory approvals for new diagnostic tests and solutions.
Ongoing: Geographic expansion into new markets and regions.
Upcoming: Publication of clinical data supporting the efficacy and utility of the Idylla platform.

BIOGF的主要风险是什么？

Ongoing: Competition from larger diagnostic companies with greater resources.
Potential: Regulatory changes and reimbursement pressures impacting the adoption of diagnostic tests.
Potential: Technological advancements by competitors leading to obsolescence of the Idylla platform.
Ongoing: Economic downturn and reduced healthcare spending affecting demand for diagnostic solutions.
Potential: Dependence on key partnerships for revenue and growth.

BIOGF的核心优势是什么？

Innovative Idylla platform technology.
Strategic partnerships with pharmaceutical companies.
Rapid and accurate diagnostic results.
Focus on oncology and infectious diseases.

BIOGF的劣势是什么？

Negative profit margin.
Reliance on partnerships.
Limited geographic presence.
Small market capitalization.

BIOGF有哪些机遇？

Expansion of Idylla platform test menu.
Geographic expansion into new markets.
Development of new diagnostic solutions.
Increasing demand for personalized medicine.

BIOGF面临哪些威胁？

Competition from larger diagnostic companies.
Regulatory changes and reimbursement pressures.
Technological advancements by competitors.
Economic downturn and reduced healthcare spending.

BIOGF的竞争对手是谁？

Exact Sciences Corp — Focuses on early cancer detection. — (EEOIF)
Guardant Health Inc — Specializes in liquid biopsy for cancer. — (GDNSF)
Hologic Inc — Offers a broad range of diagnostic and surgical products. — (HRPMF)
QIAGEN GmbH — Provides sample and assay technologies for molecular testing. — (KDEVF)
Agilent Technologies Inc — Offers a range of analytical and diagnostic solutions. — (KIARF)

Key Metrics

MoonshotScore: 52/100

Company Profile

CEO: Roger Moody
Headquarters: Mechelen, BE
Employees: 526
Founded: 2021

AI Insight

AI analysis pending for BIOGF

OTC Tier: OTC Other
Disclosure Status: Unknown

常见问题

What does Biocartis Group N.V. do?

Biocartis Group N.V. is a molecular diagnostics company that develops and commercializes the Idylla platform, a real-time PCR system for rapid and accurate molecular testing. The company's focus is on providing diagnostic solutions for oncology and infectious diseases, enabling clinicians to make informed treatment decisions and monitor treatment progress. Biocartis offers a range of diagnostic tests for the Idylla platform, including assays for BRAF, KRAS, MSI, EGFR, and NRAS-BRAF mutations, as well as tests for infectious diseases like SARS-CoV-2. The company also collaborates with pharmaceutical companies to develop and commercialize diagnostic tests for targeted therapies, leveraging the Idylla platform's capabilities to accelerate access to biomarker information and improve patient outcomes.

What do analysts say about BIOGF stock?

AI analysis is currently pending for BIOGF stock. Generally, analysts evaluate Biocartis Group N.V. based on its growth prospects in the molecular diagnostics market, the adoption rate of its Idylla platform, and its partnerships with pharmaceutical companies. Key valuation metrics include revenue growth, gross margin, and profitability. Analysts also consider the company's competitive landscape and its ability to innovate and expand its test menu. The company's financial performance, regulatory approvals, and market trends influence analyst ratings and price targets. Investors should consult multiple sources and conduct their own due diligence before making investment decisions.

What are the main risks for BIOGF?

The main risks for Biocartis Group N.V. include competition from larger diagnostic companies, regulatory changes and reimbursement pressures, technological advancements by competitors, and economic downturns affecting healthcare spending. The company's reliance on partnerships also poses a risk, as the success of its collaborations depends on the performance of its partners. Additionally, Biocartis faces risks related to the development and commercialization of new diagnostic tests, including regulatory approvals, clinical trial results, and market adoption. The company's negative profit margin and limited geographic presence also present challenges to its long-term growth and profitability. Investors should carefully consider these risks before investing in BIOGF.